Hormone therapy as a management strategy for lung metastasis after 5 years of endometrial cancer: A case report and literature review

Medicine (Baltimore). 2017 Dec;96(51):e9223. doi: 10.1097/MD.0000000000009223.

Abstract

Rationale: Endometrial cancer patients with lung metastases are rare, and more rarely with long-term management of progesterone after recurrence.

Patient concerns: Informed consent of the patients and their families.

Diagnoses: Endometrial cancer (IVB) (Refer to 2009 FIGO stag of endometrial cancer).

Interventions: the patient was treated with Megestrol Acetate Dispersible Tablets (trade name Yilizhi), 160 mg, orally, once daily, without interruption.

Outcomes: The patient has been treated with progesterone therapy for stable conditions and her survival time is already roughly a decade (December 2006-October 2016).

Lessons: Hormone therapy may as a long-term management for hormone receptor-positive patients with recurrent endometrial cancer.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma / secondary
  • Adenocarcinoma / surgery*
  • Administration, Oral
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Biopsy, Needle
  • Endometrial Neoplasms / diagnosis
  • Endometrial Neoplasms / surgery*
  • Female
  • Follow-Up Studies
  • Humans
  • Hysterectomy / methods
  • Immunohistochemistry
  • Lung Neoplasms / diagnostic imaging
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / secondary*
  • Megestrol / therapeutic use*
  • Middle Aged
  • Neoplasm Invasiveness / pathology
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Risk Assessment
  • Time Factors
  • Tomography, X-Ray Computed / methods
  • Treatment Outcome
  • Uterine Hemorrhage / diagnosis
  • Uterine Hemorrhage / etiology

Substances

  • Antineoplastic Agents, Hormonal
  • Megestrol